Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG: 0874)
Hong Kong
· Delayed Price · Currency is HKD
17.62
-0.18 (-1.01%)
Jan 3, 2025, 4:08 PM HKT
Guangzhou Baiyunshan Pharmaceutical Holdings Company Revenue
Guangzhou Baiyunshan Pharmaceutical Holdings Company had revenue of 18.02B CNY in the quarter ending September 30, 2024, a decrease of -1.08%. This brings the company's revenue in the last twelve months to 76.39B, up 3.00% year-over-year. In the year 2023, Guangzhou Baiyunshan Pharmaceutical Holdings Company had annual revenue of 75.52B with 6.68% growth.
Revenue (ttm)
76.39B CNY
Revenue Growth
+3.00%
P/S Ratio
0.34
Revenue / Employee
2.72M CNY
Employees
28,048
Market Cap
44.83B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 75.52B | 4.73B | 6.68% |
Dec 31, 2022 | 70.79B | 1.77B | 2.57% |
Dec 31, 2021 | 69.01B | 7.34B | 11.90% |
Dec 31, 2020 | 61.67B | -3.28B | -5.05% |
Dec 31, 2019 | 64.95B | 22.72B | 53.79% |
Dec 31, 2018 | Pro | Pro | Pro |
Jan 1, 2018 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 26.04B |
Hansoh Pharmaceutical Group Company | 13.00B |
JD Health International | 58.84B |
WuXi Biologics | 18.39B |
Sinopharm Group | 634.32B |
Innovent Biologics | 8.01B |
Sino Biopharmaceutical | 29.86B |
CSPC Pharmaceutical Group | 33.53B |